News & Media

    Charleston Laboratories, Inc. Expands Senior Management Team with Two Key Appointments in Core Business Areas of Medical & Commercialization

    -Thomas Smith, M.D. Joins as Chief Medical Officer and
    Terrence Terifay Joins as Chief Commercial Officer-

    Jupiter, Florida – January 24, 2017 – Charleston Laboratories, Inc. today announced two key additions to its senior management team. These additions will help propel the Company forward in its mission to bring to the market new and valuable CNS & Respiratory products to prevent the burdensome side effects related to opioid and other analgesic products.

    Thomas Smith, M.D. joined Charleston Laboratories as its Chief Medical Officer. As CMO, Dr. Smith will collaborate with the executive team in setting corporate strategy to develop late phase medical and clinical strategies for current and future products. Tom will also be working closely with various global medical and regulatory agencies to implement these strategies. Dr. Smith brings with him more than twenty-five years of experience from his time in a variety of leadership roles at various major pharmaceutical companies, including Chief Medical Officer at Ameritox, Mallinckrodt and Covidien, and as a clinical investigator and private practitioner.

    “I am incredibly excited about joining Charleston Laboratories’ team, as we determine the path for and advance the Company’s broad-ranging analgesic portfolio,” commented Dr. Smith. “I believe these expansive clinical programs are poised to bring valuable advancements to the field of pain management.”

    Terrence W. Terifay has also joined Charleston Laboratories as its Chief Commercial Officer. In his role, Terry will lead Charleston Laboratories’ commercialization efforts, including building and overseeing the Company’s commercial infrastructure to support its robust pipeline of fixed dose combination products. Terry has more than twenty years of experience in the pharmaceutical industry, including executive roles responsible for corporate strategy, commercial operations, marketing, sales, market access and customer insights/analytics. Most recently, Terry was the Senior Vice President, Chief Commercial Officer at OptiNose, where he led the commercial organization and business development. Prior to OptiNose, Terry held executive roles with Mallinckrodt Pharmaceuticals, Covidien and Cephalon.

    “I am thrilled to work with the leadership team to develop and execute a plan that will truly maximize the value of the company’s product pipeline,” stated Mr. Terifay. “Charleston Laboratories presents a unique opportunity for me and I am looking forward to the continued growth of the organization and the transformation into a commercial business.”

    Charleston Laboratories also announced that Joe Hazelton has assumed the role of Chief Operating Officer and Ryan Baker the Chief Strategy Officer position.

    “These new hires and senior roles are key to Charleston Laboratories’ continued execution of its business plan and future growth,” said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories. “I am excited to have such talented, experienced individuals on board as we take the next big steps in the advancement of our business.”

    About Charleston Laboratories, Inc.

    Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research, development and commercialization of novel pain products to prevent the burdensome side effects related to opioid analgesics and other analgesic products. In August 2014, the Company entered a strategic collaboration with Daiichi Sankyo, Inc. for the development and U.S. commercialization of Charleston Laboratories’ investigational hydrocodone-based products, including its lead candidate CL-108.

    Charleston Laboratories’ product pipeline seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV). Charleston Laboratories intends to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products. For more information, please visit


    Megan Driscoll